检索结果-南通市图书馆

Expanding the Therapeutic Spectrum of Artemisinin:Activity Against Infectious Diseases Beyond Malaria and Novel Pharmaceutical Developments

在线全文

学校读者我要写书评

暂无评论

world Journal of Traditional chinese Medicine 2016年第2期2卷 1-23页

作者： Thomas Efferth Marta R.Romero Anna Rita Bilia Ahmed Galal Osman Mahmoud ElSohly Michael wink Rudolf bauer Ikhlas Khan Maria camilla Bergonzi Jose J.G.Marin Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry Johannes Gutenberg University Experimental Hepatology and Drug Targeting (HEVEFARM) CIBERehd IBSAL University of SalamancaCampus Miguel de Unamuno Department of chemistry "Ugo Schiff" University of Florence National center for Natural Products Research School of Pharmacy University of Mississippi ElSohly Laboratories Inc. Department of Pharmaceutics University of Mississippi Institute of Pharmacy and Molecular Biotechnology Ruprecht-Karls University Institute of Pharmaceutical Sciences Department of Pharmacognosy University of Graz Devision of Pharmacognosy Department of Biomolecular Sciences University of Mississippi

The interest of western medicine in Traditional chinese Medicine(TcM) as a source of drug leads/new drugs to treat diseases without available efficient therapies has been dramatically augmented in the last decades by the extensive work and the outstanding findings achieved within this kind of medicine. The practice of TcM over thousands of years has equipped scientists with substantial experience with hundreds of plants that led to the discovery of artemisinin(qinghaosu), which is extracted from the medicinal plant Artemisia annua L.(qinghao). The unexpected success of artemisinin in combating malaria has drawn strong attention from the scientific community towards TcM. Artemisinin was discovered by Youyou Tu in 1972. Since then, several novel pharmacological activities based on the well-known properties of the sesquiterpene lactone structure with the oxepane ring and an endoperoxide bridge have been unravelled. Beyond malaria, artemisinin and its derivatives(artemisinins) exert profound activities towards other protozoans(Leishmania, Trypanosoma, amoebas, Neospora caninum, and Eimeria tenella), trematodes(Schistosoma, liver flukes), and viruses(human cytomegalovirus, hepatitis B and c viruses). Less clear is the effect against bacteria and fungi. Based on the promising results of artemisinin and the first generation derivatives(artesunate, artemether, arteether), novel drug development strategies have been *** included the synthesis of acetal-and non-acetal-type artemisinin dimeric molecules as well as developing nanotechnological approaches, ***-based liposomes, niosomes, micelles, solid lipid nanocarriers, nanostructured lipid carriers, nanoparticles, fullerenes and nanotubes. The current review presents an overview on different aspects of artemisinins, including sources, chemistry, biological/pharmacological properties, types of infectious pathogens that are susceptible to artemisinins in vitro and in vivo, in addition to the advancement in

关键词： Artemisinin derivatives Artemisia annua Asteraceae Antimalarial drugs Anti-pathogen activity Antiviral properties Artemisinin-loaded nanocarriers Traditional chinese Medicine

Total Hadronic cross Sections

在线全文

学校读者我要写书评

暂无评论

chinese Physics c 2014年第9期 537-540页

作者： K.A.Olive K.Agashe c.Amsler M.Antonelli J.-F.Arguin D.M.Asner H.Baer H.R.Band R.M.Barnett T.Basaglia c.w.bauer J.J.Beatty V.I.Belousov J.Beringer G.Bernardi S.Bethke H.Bichsel O.Biebe E.Blucher S.Blusk G.Brooijmans O.Buchmueller University of Minnesota School of Physics and Astronomy 116 church St.S.E. Minneapolis MN 55455 USA University of Maryland Department of Physics college Park MD 20742-4111 USA Albert Einstein center for Fundamental Physics Universitat Bern cH-3012 Bern Switzerland Lab.Nazionali di Frascati dell'INFN cP 13 via E.Fermi 40 I-00044 Frascati(Roma) Italy Departement de physique Universite de Montreal c.P.6128 succ.centre-ville Montreal(Quebec) H3c 3J7 canada Pacific Northwest National Laboratory 902 Battelle Boulevard Richland wA 99352 USA Department of Physics and Astronomy University of Oklahoma Norman OK 73019 USA Department of Physics University of wisconsin Madison wI 53706 USA Physics Division Lawrence Berkeley National Laboratory 1 cyclotron Road Berkeley cA 94720 USA cERN European Organization for Nuclear Research cH-1211 Geneve 23 Switzerland Department of Physics The Ohio State University 191 w.woodruff Ave. columbus OH 43210 cOMPAS Group Institute for High Energy Physics RU- 142284 Protvino Russia LPNHE IN2P3-cNRS et Universites de Paris 6 et 7 F-75252 Paris France Max-Planck-Institute of Physics 80805 Munich Germany Department of Physics University of washington Seattle wA 98195 USA Ludwig-Maximilians-Universitat Fakultdt für Physik Schellingstr.4 D-80799 München Germany Enrico Fermi Institute and Department of Physics University of chicago chicago IL 60637-1433 USA Department of Physics Syracuse University Syracuse NY 13244 USA Department of Physics columbia University 538 w.120th Street New York NY 10027 USA High Energy Physics Group Blackett Laboratory Imperial college Prince consort Road London Sw7 2AZ UK Jefferson Lab 12000 Jefferson Ave. Newport News VA 23606 USA Department of Physics University of Virginia PO Box 400714 charlottesville VA 22904 USA Fermi National Accelerator Laboratory P.O.Box 500 Batavia IL 60510 USA Kavli Institute for cosmological Physics University of chicago chicago IL 60637-1433 USA Department of Physics and Astronomy University of Sussex Falmer Brighton BN1 9QH UK Department o

(Updated September 2013,cOMPAS group,fflEP,Protvino)This updated version of the total hadronic cross sections review is based on the first half of 2013 update of the database for total cross section and the ratio of the real-to-imaginary parts of the forward elastic scattering hadronic *** data on total pp coUisions cross sections from cERN-LHc-TOTEM[1]and new data from cosmic rays experiment PAO[2]were *** use a procedure for ranking models as described in[3]to identify the safest parameterizations for ***,the models giving the best fit of accelerator data also reproduce the experimental cosmic ray nucleon-nucleon data extracted from nucleon-air data with no

关键词： Total Hadronic cross Sections data

High-energy collider parameters

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

chinese Physics c 2014年第9期 392-396页

HIGH-ENERGY cOLLIDER PARAMETERS:e+e-colliders（I）Updated in September 2013 with numbers received from representatives of the colliders（contact ***,LBNL）.The table shows parameter values as achieved by July 1,*** are,where appropriate,r.m.s.;unless noted otherwise,energies refer to beam energy;H and V indicate horizontal and vertical directions;*** for *** for the defunct SPEAR,DORIS,PETRA,PEP,TRISTAN,and VEPP-2M colliders may be found in our 1996 edition（***.D54,1 July 1996,Part I）.

关键词： LHc Pb High-energy collider parameters length cERN BEPc high MHz exp cell KEK

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

硫代硫酸钠是治疗钙化防御的新选择

世界核心医学期刊文摘（皮肤病学分册） 2006年第10期2卷 46-47页

作者： Meissner M. bauer R. Beier c. 张路坤 Johann wolfgang Goethe University Department of DermatologyTheodor-Stern-Kai 7DE-60590 Frankfurt am MainGermany Dr.

A 35-year-old haemodialysis-dependent woman with chronic renal failure developed large,very painful necrotic ulcers and necrosis on the thighs,buttocks and the abdomen with signs of fast *** skin biopsy specimens showed a broad necrosis of the epidermis and thrombosed dermal vessels with focal calcium deposits within the *** addition,laboratory findings presented an increased product of serum calcium and phosphate ***,we diagnosed calciphylaxis on the basis of clinical,biochemical and histopathological *** initiated a therapy in which our patient was treated with intravenous sodium thiosulphate 3 times *** after 2 weeks of treatment,no new lesions were detectable and there was a dramatic pain *** the following 4 weeks,a successive decline of the ulcers and the healing of individual tissue defects could be *** months after the start of the therapy,the patient underwent successful renal ***,the intravenoustherapy of calciphylaxis with sodium thiosulphate might be a new effective alternative in the treatment of this life-threatening disease.

关键词：钙化防御硫代硫酸慢性肾功能不全血液透析活检标本移植术血栓形成钙沉积坏死性病理学诊断

在线全文

学校读者我要写书评

暂无评论

新生儿成熟度和产后日龄对血清钾水平的影响

中国当代儿科杂志 2000年第1期2卷 4-7页

作者：肖昕 Karl bauer Hans Versmold 暨南大学医学院附属第一医院儿科广州510632 Kinderklinik und Poliklinik Universitatsklinikum Benjamin Franklin Kinderklinik und Poliklinik Universitatsklinikum Benjamin Franklin

目的　探讨新生儿成熟度和产后日龄对血清钾浓度的影响。方法　回顾性分析了胎龄为 2 4～ 2 8周 (A组 ) ,2 9～ 3 2周 (B组 ) ,3 3～ 3 6周 (c组 )和 3 7～ 4 2周 (D组 )新生儿生后 1～ 72h内的血清钾水平及其变化。结果　①新生儿的胎... 详细信息

目的　探讨新生儿成熟度和产后日龄对血清钾浓度的影响。方法　回顾性分析了胎龄为 2 4～ 2 8周 (A组 ) ,2 9～ 3 2周 (B组 ) ,3 3～ 3 6周 (c组 )和 3 7～ 4 2周 (D组 )新生儿生后 1～ 72h内的血清钾水平及其变化。结果　①新生儿的胎龄、体重和尿量与血清钾水平存在着线性关系。②生后 1～ 2 4h ,A组新生儿的血清钾水平最高 ,B组次之 ,c和D组相当 ,为最低。生后 4 8h内 ,A和B组的血清钾水平开始下降 ,并于 72h内下降至c和D组新生儿水平。c和D组新生儿生后 72h内的血清钾水平无明显变化。③A ,B和c组早产儿生后 2 4h内高钾血症 (≥7.0mmol/L)发生率分别为 2 0 .0 % ,12 .5%和 4 .0 % ;2 4例高钾血症患儿经常规治疗后 ,14例 (58.3 % )于 72h内血钾降至 7.0mmol/L以下并存活 ;10例 (4 1.7% )高钾血症状态持续存在 ,其中 7例死亡。D组足月儿于生后 72h内未出现高钾血症。结论　新生儿的成熟度和产后胎龄影响血清钾水平 ;极不成熟新生儿 (2 4～ 3 2周 )在生后 2 4h内具有较高的血清钾水平 ,继之随生后日龄的增加而降低 ;早产儿可有致命性高钾血症存在 ,常规治疗仅部分有效。

关键词：新生儿高钾血症成熟度产后日龄

在线全文

学校读者我要写书评

暂无评论

用5-位取代的8羟基喹啉液液萃取铝和镓

湿法冶金 1988年第3期 52-57页

作者： D.bauer 才锡民

合成了一系列5-位取代的8羟基喹啉并研究了它们在强碱性介质中（3.5MNaOH）萃取分离镓和铝的性能。在合成的化合物中,只有YEN10和和YAN5(分别带有支链c10H21—cH c—c10H2l和c5H11一cH—cH11H23)萃取镓离子,所萃取络合物是Ga（YAN5）和G... 详细信息

合成了一系列5-位取代的8羟基喹啉并研究了它们在强碱性介质中（3.5MNaOH）萃取分离镓和铝的性能。在合成的化合物中,只有YEN10和和YAN5(分别带有支链c10H21—cH c—c10H2l和c5H11一cH—cH11H23)萃取镓离子,所萃取络合物是Ga（YAN5）和Ga（YEN10）2（OH）2Na+。萃取常数分别是107·5和104,而对铝的萃取常数分别是107·7和103·5。但其中YAN5不能从铝溶液中选择性萃取镓。两相传质速率正比于镓和萃取剂浓度。若速率用mol/m2·s表示,浓度用mol/L表示,则YAN5和YENl0的相传质常数分别是1.2×10-5和1.05×10-5。这些值均比Kelexl00的相应值低,界面测量结果表明,5-位取代的分子在界面被浓缩的程度要小于Kelex100。

关键词：羟基喹啉萃取剂浓度碱性介质萃取分离传质速率液液萃取辛醇有机相碳原子分配系数

应用数字皮肤镜筛检皮肤恶性黑色素瘤高危人群

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（皮肤病学分册） 2005年第8期1卷 10-11页

作者： bauer J. Blum A. Strohhcker U. Garbe c. 党倩丽 acker Department of Dermatology Eberhard- Karls- University Liebermeisterstr. 25 72076 Tü bingen Germany BR.

Background: Dermoscopy has improved the sensitivity and specificity of clinical diagnosis of melanoma from 60% to over 90% . However, in order not to miss melanoma a certain percentage of suspicious but benign lesions has to be excised. Objectives: To evaluate the dermoscopic changes and the rates of excision in benign melanocytic naevi and cutaneous malignant melanoma in long- term follow- up of high- risk patients using digital dermoscopy. Methods: Digital dermoscopic images of 2015 atypical melanocytic naevi in 196 high- risk patients were analysed retrospectively. Among others, the following data were collected for each naevus: changes in surface area, overall architecture, dermoscopic patterns and distribution of pigmentation. All tumours suspicious for melanoma or showing asymmetrical changes were excised. Results During a median follow- up time of 25 months 128 (6.4% ) of all naevi showed changes in size or architecture. Eighty- six per cent of all changes in patients who attended more than one visit were observed at the first follow- up visit. Thirty- three lesions showing changes were excised and two melanomas in situ and 31 melanocytic naevi were diagnosed. conclusions: Follow- up examinations using digital dermoscopy revealed unchanged morphology in the large majority of melanocytic naevi. Excisions were only performed in cases of asymmetrical growth, asymmetrical changes of pigmentation, or development of dermoscopic features indicative of melanoma. The ratio of 33 lesions excised in order to identify two melanomas in situ seems reasonable and may be further reduced in future.

关键词：筛检高危人群黑色素瘤色素痣大体结构可疑病例非典型性增生黑色素沉着临床诊断特征显示